CA3291392A1 - Conjugué anticorps anti-pdl1-médicament et utilisation - Google Patents

Conjugué anticorps anti-pdl1-médicament et utilisation

Info

Publication number
CA3291392A1
CA3291392A1 CA3291392A CA3291392A CA3291392A1 CA 3291392 A1 CA3291392 A1 CA 3291392A1 CA 3291392 A CA3291392 A CA 3291392A CA 3291392 A CA3291392 A CA 3291392A CA 3291392 A1 CA3291392 A1 CA 3291392A1
Authority
CA
Canada
Prior art keywords
drug conjugate
pdl1 antibody
pdl1
antibody
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3291392A
Other languages
English (en)
Inventor
Yongqiang SHAN
Hongbin SONG
Ge Song
Jiahao JIANG
Wentao Zhang
Original Assignee
Shanghai Henlius Biologics Co Ltd
Shanghai Henlius Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Henlius Biologics Co Ltd, Shanghai Henlius Biotech Inc filed Critical Shanghai Henlius Biologics Co Ltd
Publication of CA3291392A1 publication Critical patent/CA3291392A1/fr
Pending legal-status Critical Current

Links

CA3291392A 2023-05-09 2024-05-09 Conjugué anticorps anti-pdl1-médicament et utilisation Pending CA3291392A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202310513959.4 2023-05-09
CN202311311898.X 2023-10-10

Publications (1)

Publication Number Publication Date
CA3291392A1 true CA3291392A1 (fr) 2026-03-01

Family

ID=

Similar Documents

Publication Publication Date Title
CA3256212A1 (fr) Conjugués anticorps-médicament, procédés de préparation et utilisation associées
EP3797796A4 (fr) Conjugué anticorps-médicament et son utilisation
AU2021359562A9 (en) Antibody-drug conjugate and application thereof
EP4386006A4 (fr) Conjugué anticorps-médicament et son application
AU2022205057A9 (en) B7h4-targeted antibody-drug conjugates and methods of use thereof
IL302122A (en) Antibody-drug conjugation and its application
EP4223785A4 (fr) Composition pharmaceutique comprenant un conjugué anticorps-médicament, et utilisation de la composition pharmaceutique
IL326527A (en) Compound and antibody-drug conjugate containing it
CA3265517A1 (fr) Conjugués anticorps-médicament de facteur tissulaire et leurs utilisations
CA3291392A1 (fr) Conjugué anticorps anti-pdl1-médicament et utilisation
CA3297005A1 (fr) Conjugué anticorps-médicament et utilisation associée
HK40121438A (en) Antibody-drug conjugate and use thereof
HK40125899A (en) Anti-bdca2 antibody-drug conjugate and use thereof
CA3278529A1 (fr) Conjugué anticorps-médicament anti-bdca2 et son utilisation
HK40116350A (en) Antibody-drug conjugate and use thereof
CA3263031A1 (fr) Conjugué anticorps-médicament et son utilisation
HK40117339A (en) Anti-b7h3 antibody-drug conjugate and use thereof
HK40121726A (en) Antibody-drug conjugate and use thereof
HK40130441A (zh) 抗体-药物偶联物及其用途
HK40106517A (zh) 抗体药物偶联物及其应用
HK40117803A (en) B7h4 antibody-drug conjugate and use thereof
HK40111932A (en) Her3 antibody-drug conjugate and use thereof
CA3249798A1 (fr) Conjugué anticorps-médicament anti-her3 et son utilisation
HK40096914A (en) Antibody-drug conjugate and medical use thereof
CA3280288A1 (fr) Conjugué anticorps-médicament et son utilisation